Notícias Eli Lilly and Co - LLY | Ações New York Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Eli Lilly and Co (LLY)
Eli Lilly and Co (LLY) Notícias

Eli Lilly and Co (LLY)

919,74

6,02

(0,66%)

Fechado 10 Outubro 5:00PM

Atrasado por 15 minutos

920,00

0,26

(0,03%)

Após o horário de negociação: 8:12PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições